Stock Movers: 3M Profit Outlook Misses Estimates, Netflix Amends Warner Bros. Deal, GSK Acquires Rapt Therapeutics

3M's Profit Outlook Disappoints

• 📉 3M shares experienced a significant drop, falling as much as 5%, following the release of their profit forecast.
• 🎯 The company's adjusted earnings per share outlook for the year had a midpoint below analyst expectations, indicating a potential slowdown.
• 💡 Despite efforts to revamp operations, including targeting the data center space for its electrical business due to AI, and positioning for new nuclear reactors, the momentum appears to be decelerating.

Netflix's Amended Warner Bros. Deal

• 🎬 Netflix shares saw a slight increase, up over 1%, driven by news of an amended, all-cash agreement for Warner Bros. Discovery's studio and streaming business.
• 🤝 This revised deal aims to expedite the sale process, with Netflix previously agreeing to a cash and stock offer.
• 🗓️ Netflix anticipates that shareholders will be able to vote on the transaction by April, though the overall process is expected to take considerable time.

GSK Acquires Rapt Therapeutics

• 🏥 UK drug company GSK announced its agreement to acquire US-based biotech firm Rapt Therapeutics for $2.2 billion.
• 💰 The deal values Rapt Therapeutics at $58 per share, representing a 65% premium over its previous closing price.
• 🧬 Rapt Therapeutics specializes in developing treatments for patients with inflammatory and immunologic diseases.
• 🚀 GSK's acquisition is expected to grant global rights to potential protection against food allergens and aims to bolster GSK's focus on oncology medicines and immunology.